CRISPR Therapeutics AG: Q3 2024 Financial Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2024, for CRISPR Therapeutics AG (CRSP), a leading gene-editing company. The Company's primary focus is the development of CRISPR/Cas9-based therapeutics. Its most advanced asset, CASGEVY (exagamglogene autotemcel), was approved in 2023 for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia. The Company operates in collaboration with Vertex Pharmaceuticals Incorporated for the development and commercialization of CASGEVY and other programs.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $0.6 million | $0 | $1.6 million | $170.0 million |
| Net Loss | $(85.9) million | $(112.2) million | $(328.9) million | $(243.0) million |
| Loss Per Share (Diluted) | $(1.01) | $(1.41) | $(3.92) | $(3.07) |
| Operating Expenses | $110.7 million | $132.4 million | $403.6 million | $462.1 million |
| Cash & Marketable Securities | $1.94 billion (as of Sept 30, 2024) | |||
| Accumulated Deficit | $(1.33) billion (as of Sept 30, 2024) |
Note: Revenue in Q3 2024 consisted entirely of grant revenue. The significant revenue in YTD 2023 was driven by a $170 million upfront and milestone payment from Vertex recognized in Q1 and Q2 2023.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue for the nine months ended September 30, 2024, decreased by $168.4 million compared to the prior year period. This is primarily due to the absence of the $170 million Vertex collaboration revenue recognized in the first half of 2023.
- Expense Reduction: Total operating expenses decreased by $58.5 million year-over-year for the nine-month period. Research and development expenses dropped by $53.7 million, driven by a $39.6 million decrease in external R&D costs and lower facility expenses.
- Collaboration Expense: Collaboration expense, net, remained flat at $110.3 million for the nine months ended September 30, 2024, compared to the same period in 2023. This reflects the Company exercising its option to defer costs exceeding the $110.3 million annual limit under the amended Joint Development and Commercialization Agreement (JDCA) with Vertex.
- Other Income Increase: Other income, net, increased by $24.1 million year-over-year for the nine-month period, primarily due to higher interest income earned on the Company's substantial cash and marketable securities portfolio.
Outlook, Guidance, and Risks
Liquidity and Capital Resources: As of September 30, 2024, the Company held $1.94 billion in cash, cash equivalents, and marketable securities. Management expects these resources to fund operating expenses and capital expenditures for at least the next 24 months, excluding potential future proceeds from collaborations or capital raising.
Capital Raising: In February 2024, the Company completed a registered direct offering, raising approximately $280 million. Additionally, the Company maintains an At-The-Market (ATM) offering program with up to $378.6 million remaining capacity as of September 30, 2024.
Risks and Contingencies:
- Deferred Costs: The Company has deferred $44.9 million of its share of CASGEVY costs incurred in 2024. These amounts are payable to Vertex as an offset against future profitability of the CASGEVY program.
- Future Milestones: The Company is eligible for up to $160 million in future milestones under the Non-Ex License Agreement with Vertex and up to $410 million under the 2015 Collaboration Agreement, though these are currently constrained and not recognized as revenue.
- Development Risks: The Company faces standard biopharmaceutical risks, including the uncertainty of clinical trial outcomes, regulatory approvals, and the ability to achieve commercial success for CASGEVY and its pipeline candidates (CTX112, CTX131, CTX310, CTX320, CTX211).
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $1.94 billion cash position against projected burn rates, considering the Company's history of recurring losses and the timeline for CASGEVY profitability.
- Vertex Collaboration Terms: Review the specific terms of the amended JDCA regarding the $110.3 million annual cost deferral limit and the conditions under which deferred costs become payable.
- Revenue Recognition: Confirm that no significant collaboration revenue is expected in the near term, as future milestones are currently constrained under ASC 606.
- ATM Program Status: Monitor the utilization of the remaining $378.6 million ATM capacity and the impact of potential equity dilution on shareholder value.
- Clinical Progress: Track the status of ongoing clinical trials for CASGEVY (pediatric and long-term follow-up) and next-generation candidates (CTX112, CTX131, CTX310, CTX320, CTX211) as these drive future valuation.